Clinical Practice Guidelines Have Become the Basis for OMS Tariffs. What This Changes for Drug Manufacturers.
A drug can pass registration, receive a Registration Certificate (RC), and enter commercial circulation, while its sales in the state segment stay close to zero. The reason is usually the same one: the drug’s International Nonproprietary Name (INN) never made it into the Clinical Practice Guideline (CPG) for the relevant disease. Without that step, access to Compulsory Health Insurance (OMS) tariffs and to procurement under the state guarantee program is effectively closed.
As of January 1, 2025, the transition of Russian healthcare organizations to care based on CPGs is complete nationwide. This is not a technical detail for legal departments. It is a direct signal to Market Access teams: a drug’s path to the patient no longer runs through marketing or through convincing an individual physician, but through a recommendation thesis inside an approved document.
How an Expert Opinion Turned Into a Mandatory Document
Before 2022, clinical practice guidelines held the status of expert opinion. A physician could follow them, or could instead follow an industry standard of care or personal experience, and neither choice was formally a violation.
The change came in stages. Starting in early 2022, CPGs acquired mandatory status under Part 14, Article 37 of Federal Law No. 323-FZ dated November 21, 2011, «On the Basics of Health Protection of Citizens in the Russian Federation» (hereinafter, FL No. 323-FZ). The Government originally set January 1, 2024 as the deadline for completing the transition; the State Duma later pushed it back to January 1, 2025. By that date, every medical organization was required to switch to care based on the guidelines published in the Ministry of Health’s Rubricator.
As CPGs became mandatory, the status of related documents shifted too. By law, the Medical Care Standard (MCS) is developed on the basis of approved CPGs and sets average indicators for how often and how frequently drugs, medical devices, and services are used. Medical care quality criteria, in turn, are set by disease group based on care delivery procedures and on those same clinical practice guidelines. The result is a three-tier hierarchy in which each document depends directly on the one below it, with CPGs at the foundation.
What Changed When the Transition Was Completed
The completion of the transition in January 2025 coincided with updates to several Ministry of Health orders that govern the practical side of working with CPGs. Three of them directly concern manufacturers and regulatory affairs managers.
| Parameter | Before | Now |
|---|---|---|
| Status of clinical practice guidelines | Expert recommendation, mandatory status phased in | Mandatory basis for medical care nationwide (Part 14, Art. 37, FL No. 323-FZ) |
| Medical care quality criteria | Ministry of Health Order No. 203n dated May 10, 2017 | Ministry of Health Order No. 203n dated April 14, 2025, in effect from Sept 1, 2025 to Sept 1, 2031 |
| Frequency of medical commission meetings | At least once a week (Order No. 502n, 2012) | At least once a month (Ministry of Health Order No. 180n dated April 10, 2025, in effect from Sept 1, 2025) |
| Physicians completing CPG training modules | Not mandatory for guidelines published before 2022 | Mandatory IOM-CPG modules for guidelines published in the Rubricator before Jan 1, 2024, with a completion deadline of Jan 1, 2025 |
These updates landing in the same year is not a coincidence. The Ministry of Health synchronized quality control (Order No. 203n), internal review of prescriptions (Order No. 180n), and the mandatory deadline for physicians to complete IOM-CPG training with the moment CPGs became the sole legitimate basis for treatment. A drug’s mismatch with the active guideline is now checked through the same oversight loop as before, but with fewer medical commission meetings in reserve and more detailed quality criteria at the output.
How a Drug Enters a Recommendation Thesis
The procedure and timelines for developing CPGs are set by Ministry of Health Order No. 103n dated February 28, 2019 (hereinafter, Order No. 103n). Clinical practice guidelines are drafted by medical professional non-profit organizations (MPNPOs), against a list of diseases that the Ministry of Health compiles. The procedure runs through several sequential steps.
An MPNPO files notice of starting development or revision of a guideline within one month of the list being published on the Ministry’s website. It then has four months to prepare the draft and run a public discussion, including posting it online for comment from scientific and medical organizations. The finished draft goes to the Scientific and Practical Council (NPS) at the Ministry of Health, which approves it, rejects it, or sends it back for revision.
Revision of an existing CPG is mandatory at least once every three years, and Order No. 103n allows unscheduled edits no more than once every six months. In practice, a company cannot simply «add» a drug to a guideline whenever it wants: it either has to catch the scheduled revision or wait for the next six-month window.
This matters for Market Access: the manufacturer itself does not file a dossier with the MPNPO and is not a formal party to the procedure under Order No. 103n. Its only channel of influence is the scientific record: published clinical trial results, systematic reviews, and meta-analyses that the MPNPO’s working group draws on when drafting recommendation theses. The stronger the evidence base behind a drug, the higher the odds its INN gets locked into the text with a «recommended» status.
Where to Find a Drug’s Name Inside a Guideline
The standard template for a clinical practice guideline, approved by Appendix No. 2 to Order No. 103n, runs to nineteen sections, from the title page and a brief description of the disease through treatment, rehabilitation, prevention, and appendices. Three of them matter for a Market Access department.
Section VII, «Treatment,» contains the recommendation theses themselves, with INNs and their assigned Level of Evidence (LoE) and Strength of Recommendation (SoR). Appendix A3, «Reference Materials,» cross-checks the indications and doses from the theses against the drug’s package insert. Appendix B, «Information for the Patient,» describes the disease and treatment in plain language, and Order No. 103n explicitly requires this section in every CPG.
Inside the theses, a system of marks is used. If a drug is on the list of Vital and Essential Drugs, its INN is marked with two asterisks. A medical device implanted into the body under the state guarantee program is marked with three asterisks. A hash sign (#) is placed before the name of a drug used off-label, and in that case the thesis itself must cite the specific clinical studies behind that dosing regimen. For a regulatory manager, these marks are a fast way to check the status of the company’s INN in an active guideline without reading the whole document.
Why the LoE and SoR Scales Matter
Every recommendation thesis in a CPG carries two scores: Level of Evidence (LoE) and Strength of Recommendation (SoR). Both scales are set out in an appendix to Order No. 103n and are mandatory whenever a guideline is drafted or revised.
The LoE scale for treatment and prevention methods has five levels. Level 1 goes to a systematic review of randomized controlled trials with meta-analysis; level 5 goes to interventions supported only by mechanism of action or expert opinion. A separate five-level LoE scale applies to diagnostic methods, topped by systematic reviews of studies validated against a reference method.
The SoR scale is shorter, with three levels. A strong recommendation, grade A, means all clinically relevant outcomes were studied in high-quality research with consistent conclusions. A conditional recommendation, grade B, allows for incomplete outcome coverage or uneven study quality. A weak recommendation, grade C, effectively means there is no evidence of adequate quality.
For a regulatory manager, these letters are not abstractions. Failing to follow a strong (A or B) recommendation exposes the treating physician to risk during Roszdravnadzor and insurance company audits, so all else being equal a physician will choose the drug from the thesis with the higher SoR. Investment in solid research pays off specifically in reaching a strong recommendation grade: simply getting the INN mentioned in the text is not enough for a competitive edge.
From Recommendation Thesis to the OMS Tariff
Getting an INN into a clinical practice guideline opens the path to the next tier, but it does not by itself guarantee procurement. Based on the approved CPG, a Medical Care Standard is developed with average indicators for how often and how frequently the drug is used. From there, the Center for Healthcare Quality Assessment and Control (CHQAC) carries out a medico-economic evaluation and takes part in setting tariffs for clinical-statistical groups (KSG), the units through which medical care is paid for out of OMS funds.
Monitoring the CPG Rubricator is worth building into a portfolio’s regular audit as a standing Market Access task. A one-time check at product launch is not enough: time passes between a guideline’s approval and the appearance of a tariff, and the law does not set a fixed deadline for drafting the Medical Care Standard.
An INN’s presence in an active CPG is not protected from revision. Order No. 103n explicitly allows for a negative thesis, meaning a «not recommended» formulation, and the MPNPO working group can change a drug’s status at the scheduled revision, which happens at least once every three years, if the accumulated evidence has weakened or stronger competing data has appeared. For a portfolio already locked into a KSG tariff, that means keeping the scientific dossier current on an ongoing basis, not just at the point of first inclusion.
The pediatric population deserves separate attention. Part 14.1, Article 37 of FL No. 323-FZ, introduced by Federal Law No. 482-FZ dated December 30, 2021, allows including an off-label drug in a pediatric MCS or CPG, provided the requirements set by the Russian Government are met. Companies with pediatric portfolios rarely use this provision, even though it has formally been available for several years.
What Changes for Physicians, and What It Means for Companies
The tightened control loop touched not only documents but also how medical institutions organize their work. Since September 1, 2025, a new procedure governs medical commissions, approved by Ministry of Health Order No. 180n dated April 10, 2025, replacing Order No. 502n from 2012. Scheduled meetings now happen at least once a month instead of weekly, while a decision to use a drug outside the standard or the guideline for life-saving reasons still has to be recorded in the commission’s minutes.
At the same time, physicians are now required to complete Interactive Educational Modules on clinical practice guidelines (IOM-CPG) through the continuing medical education (CME/НМО) portal. For guidelines published in the Rubricator before January 1, 2024, the deadline for completing the training expired on January 1, 2025, in step with the overall transition deadline. For a company, that means the physician across the table has actually trained on the version of the guideline that carries the current status of its INN, and an appeal to «how it used to be done» no longer works in that conversation.
Article 37 of FL No. 323-FZ itself is not static either. Federal Law No. 261-FZ dated July 23, 2025 handed the authority to set the procedure and timelines for developing, revising, and applying clinical practice guidelines to the authorized federal executive body, meaning the Ministry of Health. That opens the door to an update of Order No. 103n in the next cycle or two, and regulatory teams should build a check of the order’s current version into their regular audit rather than treating the 2023 revision as permanent.
What to Do
Check the INN’s status in the Rubricator. Go to cr.minzdrav.gov.ru, confirm whether the drug is included in the active CPG for the relevant disease, and match the document’s approval date against the revision cycle: at least once every three years, no more than once every six months.
Build and document the evidence base for the LoE and SoR scales. Organize the study publications so the MPNPO working group can assign the thesis a high evidence level instead of the bottom of the scale, which rests on expert opinion alone.
Reach out to the relevant MPNPO and National Medical Research Centers before public discussion opens. The four-month discussion window for the draft guideline, counted from the notice of starting development, is the point where scientific arguments can still make it into the text.
Track two parallel tracks after the CPG is approved. Drafting the Medical Care Standard and calculating the KSG tariff run as separate procedures involving CHQAC, and inclusion in the guideline does not substitute for watching both.
Check whether Part 14.1, Article 37 of FL No. 323-FZ applies to the pediatric portfolio. If an indication is off-label but backed by publications or inclusion in foreign guidelines, assess whether the dossier meets the Government’s requirements for pediatric off-label use.
Procurement decisions are increasingly made by a commission working from a recommendation thesis with a scored evidence level, while the treating physician’s personal experience at the bedside moves into the background. That kind of market calls for a different way of working in Market Access: a scientific publication now competes for a place in a regulatory document the way price used to compete for a place in a tender. The winner is whoever builds work with the Rubricator into their regulatory strategy early, well before running into a procurement rejection.
Regulatory basis:
1. Ministry of Health Order No. 180n dated April 10, 2025, «On Approval of the Procedure for Establishing and Operating a Medical Commission at a Medical Organization»
2. Federal Law No. 323-FZ dated November 21, 2011, «On the Basics of Health Protection of Citizens in the Russian Federation,» Articles 37 and 64
3. Federal Law No. 482-FZ dated December 30, 2021 (introducing Part 14.1, Article 37 of FL No. 323-FZ)
4. Federal Law No. 261-FZ dated July 23, 2025 (amending Article 37 of FL No. 323-FZ)
5. Ministry of Health Order No. 103n dated February 28, 2019, «On Approval of the Procedure and Timelines for Developing Clinical Practice Guidelines, Their Revision, the Standard Form of Clinical Practice Guidelines, and Requirements for Their Structure, Content, and the Scientific Justification of Information Included in Clinical Practice Guidelines» (as amended September 28, 2023)
6. Ministry of Health Order No. 203n dated April 14, 2025, «On Approval of Medical Care Quality Assessment Criteria»